Hexima Limited | Pharmaceutical Application

ASX Announcements

Current pricing

Click here for today’s HXL share price information.

Hexima Appoints Executive Chairman

July 2010

Hexima confirms first transgenic corn plants under Pioneer collaboration

March 2010

PC2 certification secured for glasshouse and laboratory

February 2010

2009 Half Year Report to Shareholders

22 February 2010

Half year accounts

22 February 2010

Half year report – Appendix 4D

22 February 2010

Hexima announces research cross-licenses with Monsanto

February 2010

Hexima management changes

February 2010

Other announcements…

pharmaceutical application

Hexima is undertaking an externally funded human disease program. The program is still considered to be in the discovery stage, but the Company is encouraged by its initial findings. In November 2009, the Company announced that it intended to undertake the next stage of research, which will determine whether any of the molecules of interest progress into clinical trials over the next 2–3 years.